Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2020-01-10 Legal Proceedings Report
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a legal ruling by the Supreme Court of Delaware in favor of Ligand Pharmaceuticals, dismissing a complaint related to a Supplemental Indenture. There are no financial statements or detailed financial data presented. The document is primarily an announcement of a legal proceeding outcome, not a full audit report or annual/quarterly report. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 3550 characters, which is typical for an 8-K filing announcing a specific event. Hence, the classification is LTR with high confidence.
2020-01-10 English
PRIMARY DOCUMENT
Director's Dealing
2019-12-26 English
PRIMARY DOCUMENT
Director's Dealing
2019-12-26 English
PRIMARY DOCUMENT
Director's Dealing
2019-12-26 English
PRIMARY DOCUMENT
Director's Dealing
2019-12-26 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the approval of cash bonus payments to named executive officers for the 2019 fiscal year, including amounts and titles. This relates to changes or announcements about executive compensation and management decisions. The key section is Item 5.02, which concerns departure or election of directors or officers and compensatory arrangements. This fits the category of Board/Management Information (MANG), as it announces management compensation decisions and changes related to officers. The document is relatively short (3660 characters) and is not a full financial report or earnings release. Therefore, the best classification is MANG with high confidence.
2019-12-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.